Cempra sags as reviewers fret over Solithera worries

Cempra Inc. (NASDAQ:CEMP) plummeted $11.35 (61%) to $7.30 on Wednesday after FDA reviewers said hepatotoxicity findings from clinical studies of oral and IV Solithera solithromycin constitute a "genuine liver injury signal." The comments came in

Read the full 355 word article

User Sign In